Dic biochemical abnormal

Reading File

Finding Sources

Reading File

Here is a full breakdown of the biochemical/laboratory abnormalities in DIC:

Biochemical Abnormalities in DIC (Disseminated Intravascular Coagulation)

1. Coagulation Tests

Test	Finding	Reason
PT (Prothrombin Time)	Prolonged	Consumption and depletion of clotting factors
aPTT	Prolonged	Same mechanism; note: aPTT can be shortened in early DIC due to circulating activated factors
Thrombin Time (TT)	Prolonged	Hypofibrinogenemia + FDP interference
Fibrinogen	Low (<100 mg/dL in severe cases)	Consumed in intravascular fibrin formation

2. Fibrin Markers

Test	Finding	Significance
D-dimer	Markedly elevated	Cross-linked fibrin degradation; most sensitive marker
FDPs (Fibrin/Fibrinogen Degradation Products)	Elevated	Reflect ongoing fibrinolysis

3. Hematology

Test	Finding	Reason
Platelet count	Low (thrombocytopenia)	Consumption in microthrombi
Hemoglobin / Hematocrit	Low (anemia)	RBC destruction
Peripheral blood smear	Schistocytes and helmet cells	RBCs sheared by fibrin strands in microvasculature = microangiopathic hemolytic anemia (MAHA)

4. Coagulation Factor Levels

Factors V and VIII: Markedly decreased (consumed by thrombin)
Antithrombin: Decreased (consumed)
Protein C and Protein S: Decreased

5. Other Findings

Antithrombin III: Low
Plasminogen: Low (consumed by fibrinolysis)
Alpha-2 antiplasmin: Low

ISTH Scoring System for Overt DIC

Parameter	Finding	Score
Platelet count	>100 k/μL = 0; <100 k/μL = 1; <50 k/μL = 2
D-dimer	No increase = 0; moderate increase = 2; strong increase = 3
PT prolongation	<3 sec = 0; 3-6 sec = 1; >6 sec = 2
Fibrinogen	>1 g/L = 0; <1 g/L = 1

Score ≥ 5 = compatible with overt DIC (repeat daily). Score < 5 = suggestive of non-overt/early DIC.

Summary Mnemonic: "Low Plate, Low Fib, High FDP, Long PT"

Low platelets
Low fibrinogen
High D-dimer / FDPs
Long PT / aPTT
Schistocytes on smear (MAHA)

Sources: Tietz Textbook of Laboratory Medicine, 7th Ed., p. 3128; Henry's Clinical Diagnosis and Management by Laboratory Methods; Tintinalli's Emergency Medicine

Key clinical point: No single lab test confirms DIC. It is a pattern - you need to interpret all tests together in the context of an underlying predisposing condition (sepsis, malignancy, obstetric complication, major trauma).

Cause

The causes of DIC are well-established from the previous context already retrieved. I have sufficient information to answer directly without additional tool calls.

Causes of DIC

DIC is never a primary disease - it always occurs secondary to an underlying condition that triggers systemic coagulation activation.

1. Infections (Most Common Cause)

Gram-negative sepsis (10-20% develop DIC) - endotoxins stimulate monocytes and endothelial cells to express tissue factor
Gram-positive sepsis
Viral infections (HIV, CMV, varicella, hemorrhagic fever viruses)
Fungal infections
Rocky Mountain Spotted Fever - direct endothelial damage
Higher risk in asplenic patients and those with cirrhosis

2. Malignancy

Acute Promyelocytic Leukemia (APL / M3) - most common leukemia to cause DIC; blast cells release procoagulant enzymes; worsens at time of chemotherapy-induced cell lysis
Adenocarcinomas (mucin-secreting) - tend toward thrombosis (Trousseau's syndrome)
Prostate cancer - tends toward bleeding
Lymphoma
Solid tumors (often chronic/compensated DIC)

3. Obstetric Complications

Condition	Type of DIC
Placental abruption	Acute hemorrhagic DIC
Amniotic fluid embolism	Acute hemorrhagic DIC
Septic abortion	Acute DIC
Intrauterine fetal death (retained dead fetus)	Chronic, prothrombotic DIC
HELLP syndrome	Acute DIC
Placenta previa	Acute DIC

4. Trauma & Tissue Injury

Brain injury (rich in thromboplastin)
Crush injury
Burns
Hypothermia / hyperthermia
Fat embolism
Rhabdomyolysis
Hypoxia
Major surgery (especially aortic arch, pulmonary artery bypass)

5. Organ Injury

Acute hepatic failure - tissue factor released from injured hepatocytes; liver also fails to clear activated factors
Pancreatitis - activates the coagulation cascade via proteolytic enzymes

6. Vascular Disorders

Large aortic aneurysm (chronic DIC that can become acute at surgery)
Giant hemangioma (Kasabach-Merritt syndrome)
Vasculitis
Multiple telangiectasias

7. Transfusion Reactions

Acute hemolytic transfusion reaction - severe bleeding, shock, and acute renal failure with DIC

8. Envenomation

Rattlesnake and other viper bites - venom damages endothelial cells
Bleeding is often less severe than lab values suggest

9. Other

Acute Respiratory Distress Syndrome (ARDS) - microthrombi in pulmonary vessels; 20% of ALI patients develop DIC, and 20% of DIC patients develop ALI
Hemolytic uremic syndrome (HUS)
Transplant rejection

Common Mnemonic: "STOP Making New Thrombi"

Letter	Category
S	Sepsis
T	Trauma
O	Obstetric complications
P	Promyelocytic leukemia / malignancy
M	Massive transfusion / hemolytic reaction
N	Necrosis (liver, pancreas)
T	Toxins / envenomation

Sources: Tintinalli's Emergency Medicine; Tietz Textbook of Laboratory Medicine, 7th Ed.; Henry's Clinical Diagnosis and Management by Laboratory Methods

Treatment

Finding Sources

Reading File

Treatment of DIC

The cornerstone principle: treat the underlying cause first. DIC is always secondary - without eliminating the trigger, all other interventions are temporary.

Step 1: Treat the Underlying Cause (MOST IMPORTANT)

Cause	Specific Treatment
Sepsis	Antibiotics + source control
Obstetric complication	Delivery of fetus/placenta
Malignancy (APL)	All-trans retinoic acid (ATRA)
Trauma	Surgical hemorrhage control
Transfusion reaction	Stop transfusion immediately
Abscess	Surgical drainage

Many episodes of DIC are self-limited once the trigger is removed and require only general supportive care.

Step 2: Replacement Therapy (for Active Bleeding)

Indicated when the patient has active bleeding, requires an invasive procedure, or has significant thromboembolism / skin necrosis / acral ischemia.

Product	Indication	Threshold
Fresh Frozen Plasma (FFP)	Prolonged PT/aPTT (>2x normal) + active bleeding	Replenishes all clotting factors
Cryoprecipitate	Low fibrinogen + active bleeding	Fibrinogen <100 mg/dL (<1 g/L)
Fibrinogen concentrate	Persistent hypofibrinogenemia despite FFP	Fibrinogen <100 mg/dL
Platelet transfusion	Thrombocytopenia + active bleeding	Platelets <50,000/mm³
Vitamin K	Prolonged PT	Parenteral administration
Packed RBCs	Symptomatic anemia from MAHA	As needed

Monitor response by: slowing of bleeding, falling FDPs, rising platelet count and fibrinogen. Normalization of clotting times occurs later and is a less reliable early monitor.

Step 3: Anticoagulation (for Thrombosis-Predominant DIC)

Heparin is used selectively when fibrin deposition and thrombosis predominate over bleeding.

When to consider heparin:

Purpura fulminans
Retained dead fetus (before delivery)
Giant hemangioma (Kasabach-Merritt)
Acute promyelocytic leukemia (APL)
Chronic/compensated DIC with thrombosis

Low-molecular-weight heparin (LMWH) is recommended for VTE prophylaxis when:

Bleeding is absent
Platelet count >30,000/mm³

Step 4: Antifibrinolytics

Agent	Use
Tranexamic acid	Trauma-related DIC only - reduces mortality
Tranexamic acid	Generally AVOIDED in other DIC (risk of worsening thrombosis)
Epsilon-aminocaproic acid (EACA)	Similarly avoided unless hyperfibrinolysis confirmed

What Does NOT Have Proven Benefit in DIC

Prothrombin complex concentrate (PCC)
Recombinant factor VIIa (rFVIIa) - high thrombosis risk
Activated protein C (drotrecogin alfa - withdrawn)

Treatment Summary by Clinical Phenotype

DIC Phenotype	Dominant Problem	Primary Approach
Bleeding-predominant	Factor/platelet consumption	FFP + cryoprecipitate + platelets
Thrombosis-predominant	Microvascular fibrin deposition	LMWH / heparin
Sepsis-associated	Both	Treat infection + supportive replacement
Trauma-induced coagulopathy	Hyperfibrinolysis	Tranexamic acid + blood products
APL-associated	Prominent fibrinolysis	ATRA + blood products
Chronic/compensated	Prothrombotic	LMWH prophylaxis

Sources: Tintinalli's Emergency Medicine, A Comprehensive Study; Rosen's Emergency Medicine, Concepts and Clinical Practice

This is a shared conversation. Sign in to Orris to start your own chat.